MoonLake Immunotherapeutics (MLTX) Income from Non-Controlling Interests (2022 - 2025)
MoonLake Immunotherapeutics (MLTX) posted quarterly Income from Non-Controlling Interests of $77000.0 for Q1 2026, up 112.52% year-over-year from $36231.8 in Q1 2025, and up 102.84% quarter-over-quarter from -$2.7 million in Q4 2025.
Powered by 
Analysis
MoonLake Immunotherapeutics (MLTX) Income from Non-Controlling Interests (2022 - 2025) Analysis & Trends
MoonLake Immunotherapeutics' Income from Non-Controlling Interests history runs 5 years deep, the most recent figure standing at $77000.0 for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests rose 112.52% year-over-year to $77000.0; the TTM figure through Mar 2026 stood at -$4.4 million (down 399.12% YoY), while the FY2025 annual figure was -$5.1 million, down 290.73% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at $77000.0, up from -$2.7 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $9.4 million in Q4 2023, with the low at -$5.3 million in Q2 2022.
- The 5-year median for Income from Non-Controlling Interests is $50736.0 (2023), against an average of $320810.7.
- The sharpest annual moves came in 2023 and 2025: Income from Non-Controlling Interests soared 4363.67% in 2023, then plunged 437.91% in 2025.
- MoonLake Immunotherapeutics' Income from Non-Controlling Interests stood at $639890.0 in 2022, then jumped by 1368.78% to $9.4 million in 2023, then tumbled by 76.84% to $2.2 million in 2024, then slumped by 224.53% to -$2.7 million in 2025, then surged by 102.84% to $77000.0 in 2026.
- Business Quant data shows MLTX's Income from Non-Controlling Interests at $77000.0 in Q1 2026, -$2.7 million in Q4 2025, and -$965000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | MoonLake Immunotherapeutics | 1.10 Bn | 566.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -588,000.00 |
| Sep 30, 2025 | -969,000.00 |
| Jun 30, 2025 | -859,000.00 |
| Mar 31, 2025 | -656,000.00 |
| Dec 31, 2024 | -790,000.00 |
| Sep 30, 2024 | -733,000.00 |
| Jun 30, 2024 | -492,000.00 |
| Mar 31, 2024 | -302,000.00 |
| Dec 31, 2023 | -450,457.00 |
| Sep 30, 2023 | -2.19 Mn |
| Jun 30, 2023 | -2.30 Mn |
| Mar 31, 2023 | -3.22 Mn |
| Dec 31, 2022 | 639,890.00 |
| Sep 30, 2022 | -4.63 Mn |
| Jun 30, 2022 | -5.30 Mn |